Brief: Epigenomics Confirms Its 2020 Outlook

Epigenomics AG

07/05/2020 07:28

May 7 (Reuters) - Epigenomics AG  ECXn.DE :
    * EPIGENOMICS AG REPORTS 2020 FIRST QUARTER FINANCIAL
RESULTS
    * PRODUCT REVENUE IN Q1 2020 DECREASED FROM EUR 322 THOUSAND
TO
EUR 219 THOUSAND YEAR-ON-YEAR
    * Q1 TOTAL REVENUE FELL YEAR-ON-YEAR TO EUR 239 THOUSAND (Q1
2019:
EUR 331 THOUSAND)
    * Q1 EBITDA BEFORE FOR SHARE-BASED PAYMENT EXPENSES WAS EUR
-2,641
THOUSAND IN REPORTING PERIOD (Q1 2019: EUR -2,958 THOUSAND)
    * Q1 NET LOSS FOR PERIOD WAS EUR -2,982 THOUSAND (Q1 2019:
EUR
-3,018 THOUSAND)
    * AS OF MARCH 31, 2020, COMPANY HAD CASH AND CASH
EQUIVALENTS OF
EUR 10,983 THOUSAND
    * CONFIRMS ITS OUTLOOK FOR FISCAL YEAR 2020
    * FOR FULL YEAR 2020, EPIGENOMICS' EBITDA BEFORE SHARE-BASED
PAYMENT EXPENSES IS PROJECTED TO RANGE BETWEEN EUR -10.5 MILLION
AND EUR -12.5 MILLION
    * CONTINUES TO EXPECT 2020 REVENUE WITHIN RANGE OF EUR 1.0
MILLION
TO EUR 2.0 MILLION

Source text for Eikon:  ID:nEQ61MFG5a 
Further company coverage:  ECXn.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))